Eintrag weiter verarbeiten
Verfügbar über Online-Ressource

Interventional left atrial appendage closure affects the metabolism of acylcarnitines

Gespeichert in:

Veröffentlicht in: International journal of molecular sciences 19(2018,2) Artikel-Nummer 500, 12 Seiten
Personen und Körperschaften: Fastner, Christian (VerfasserIn), Behnes, Michael (VerfasserIn), Sartorius, Benjamin (VerfasserIn), Wenke, Annika (VerfasserIn), Lang, Siegfried (VerfasserIn), Yücel, Gökhan (VerfasserIn), Sattler, Katherine (VerfasserIn), Rusnak, Jonas (VerfasserIn), Saleh, Ahmad (VerfasserIn), Barth, Christian (VerfasserIn), Hoffmann, Ursula (VerfasserIn), Borggrefe, Martin (VerfasserIn), Akın, Ibrahim (VerfasserIn)
Titel: Interventional left atrial appendage closure affects the metabolism of acylcarnitines/ Christian Fastner, Michael Behnes, Benjamin Sartorius, Annika Wenke, Siegfried Lang, Gökhan Yücel, Katherine Sattler, Jonas Rusnak, Ahmad Saleh, Christian Barth, Kambis Mashayekhi, Ursula Hoffmann, Martin Borggrefe and Ibrahim Akin
Format: E-Book-Kapitel
Sprache: Englisch
veröffentlicht:
7 February 2018
Gesamtaufnahme: : International journal of molecular sciences, 19(2018,2) Artikel-Nummer 500, 12 Seiten
, volume:19
Schlagwörter:
acylcarnitines
atrial fibrillation
left atrial appendage
left atrial appendage closure
metabolomics
Quelle: Verbunddaten SWB
Lizenzfreie Online-Ressourcen
Details
Zusammenfassung: Background: Left atrial appendage closure (LAAC) represents the interventional alternative to oral anticoagulation for stroke prevention in atrial fibrillation (AF). The metabolism of acylcarnitines was shown to affect cardiovascular diseases. This study evaluates the influence of successful LAAC on the metabolism of acylcarnitines. Methods: Patients undergoing successful LAAC were enrolled prospectively. Peripheral blood samples for metabolomics measurements were collected immediately before (i.e., index) and six months after LAAC (i.e., mid-term). A targeted metabolomics analysis based on electrospray ionization-liquid chromatography-mass spectrometry (ESI-LC-MS/MS) and MS/MS measurements was performed. Results: 44 patients with non-valvular AF (median CHA2DS2-VASc score 4, median HAS-BLED score 4) and successful LAAC were included. Significant changes in acylcarnitine levels were found in the total cohort, which were mainly attributed to patients with impaired left ventricular and renal function, elevated amino-terminal pro-brain natriuretic peptide (NT-proBNP) and diabetes mellitus. Adjusted multivariable regression models revealed significant changes of five metabolites over mid-term follow-up: C2, C14:1, C16, and C18:1 decreased significantly (each p < 0.05); short-chain C5 acylcarnitine plasma levels increased significantly (p < 0.05). Conclusion: This study demonstrates that successful LAAC affects the metabolism of acylcarnitines at mid-term follow-up.
Beschreibung: Gesehen am 07.10.2019
Umfang: 12
ISSN: 1422-0067
DOI: 10.3390/ijms19020500